As of Nov 27
| +0.08 / +6.11%|
The 3 analysts offering 12-month price forecasts for BioLine RX Ltd have a median target of 4.00, with a high estimate of 7.00 and a low estimate of 3.50. The median estimate represents a +187.77% increase from the last price of 1.39.
The current consensus among 3 polled investment analysts is to Buy stock in BioLine RX Ltd. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.